Alberto Malesci

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11524719/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Tumour-associated macrophages as treatment targets in oncology. Nature Reviews Clinical Oncology, 2017, 14, 399-416.	12.5	2,667
2	Inflammation and Coagulation in Inflammatory Bowel Disease: The Clot Thickens. American Journal of Gastroenterology, 2007, 102, 174-186.	0.2	322
3	VEGF-A Links Angiogenesis and Inflammation in Inflammatory Bowel Disease Pathogenesis. Gastroenterology, 2009, 136, 585-595.e5.	0.6	289
4	Occurrence of Tertiary Lymphoid Tissue Is Associated with T-Cell Infiltration and Predicts Better Prognosis in Early-Stage Colorectal Cancers. Clinical Cancer Research, 2014, 20, 2147-2158.	3.2	264
5	CD3+ cells at the invasive margin of deeply invading (pT3–T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. Lancet Oncology, The, 2009, 10, 877-884.	5.1	226
6	Reduced Likelihood of Metastases in Patients with Microsatellite-Unstable Colorectal Cancer. Clinical Cancer Research, 2007, 13, 3831-3839.	3.2	221
7	Unique Role of Junctional Adhesion Molecule-A in Maintaining Mucosal Homeostasis in Inflammatory Bowel Disease. Gastroenterology, 2008, 135, 173-184.	0.6	210
8	Endoscopic submucosal dissection in patients with early esophageal squamous cell carcinoma: results from a prospective Western series. Gastrointestinal Endoscopy, 2010, 71, 715-721.	0.5	177
9	Occurrence and significance of tumorâ€associated neutrophils in patients with colorectal cancer. International Journal of Cancer, 2016, 139, 446-456.	2.3	141
10	The added value of impedance-pH monitoring to Rome III criteria in distinguishing functional heartburn from non-erosive reflux disease. Digestive and Liver Disease, 2011, 43, 542-547.	0.4	140
11	The lymphatic system controls intestinal inflammation and inflammation-associated colon cancer through the chemokine decoy receptor D6. Gut, 2010, 59, 197-206.	6.1	138
12	Multiple Pathogenic Roles of Microvasculature in Inflammatory Bowel Disease: A Jack of All Trades. American Journal of Pathology, 2008, 172, 1457-1466.	1.9	125
13	Endoscopic Mucosal Resection for Early Colorectal Neoplasia: Pathologic Basis, Procedures, and Outcomes. Diseases of the Colon and Rectum, 2009, 52, 1502-1515.	0.7	121
14	Methylation framework of cell cycle gene inhibitors in cirrhosis and associated hepatocellular carcinoma. Hepatology, 2002, 36, 427-432.	3.6	108
15	Crucial role of the protein C pathway in governing microvascular inflammation in inflammatory bowel disease. Journal of Clinical Investigation, 2007, 117, 1951-1960.	3.9	105
16	Impedance-pH reflux patterns can differentiate non-erosive reflux disease from functional heartburn patients. Journal of Gastroenterology, 2012, 47, 159-168.	2.3	102
17	Determination of CA 19-9 antigen in serum and pancreatic juice for differential diagnosis of pancreatic adenocarcinoma from chronic pancreatitis. Gastroenterology, 1987, 92, 60-67.	0.6	99
18	Tumor-associated macrophages and response to 5-fluorouracil adjuvant therapy in stage III colorectal cancer. Oncolmmunology, 2017, 6, e1342918.	2.1	90

#	Article	IF	CITATIONS
19	High efficacy of endoscopic submucosal dissection for rectal laterally spreading tumors larger than 3 cm. Gastrointestinal Endoscopy, 2013, 77, 96-101.	0.5	80
20	Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients. Journal of Autoimmunity, 2020, 114, 102511.	3.0	72
21	Serum CA 19-9 in the postsurgical follow-up of patients with pancreatic cancer. Cancer, 1987, 60, 2428-2431.	2.0	67
22	Bowel Damage as Assessed by the Lémann Index is Reversible on Anti-TNF Therapy for Crohn's Disease. Journal of Crohn's and Colitis, 2015, 9, 633-639.	0.6	65
23	Iron Metabolism in Cancer Progression. International Journal of Molecular Sciences, 2020, 21, 2257.	1.8	65
24	Unexpected role of anticoagulant protein C in controlling epithelial barrier integrity and intestinal inflammation. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 19830-19835.	3.3	63
25	Irrelevance of Microsatellite Instability in the Epidemiology of Sporadic Pancreatic Ductal Adenocarcinoma. PLoS ONE, 2012, 7, e46002.	1.1	63
26	Laparoscopic Surgery in Rectal Cancer: A Prospective Analysis of Patient Survival and Outcomes. Diseases of the Colon and Rectum, 2007, 50, 2047-2053.	0.7	62
27	Prognostic value of innate and adaptive immunity in colorectal cancer. World Journal of Gastroenterology, 2013, 19, 174.	1.4	57
28	Quantitative evaluation of RASSF1Amethylation in the non-lesional, regenerative and neoplastic liver. BMC Cancer, 2006, 6, 89.	1.1	56
29	Activation of the VEGFC/VEGFR3 Pathway Induces Tumor Immune Escape in Colorectal Cancer. Cancer Research, 2019, 79, 4196-4210.	0.4	53
30	The role of MAPK in governing lymphocyte adhesion to and migration across the microvasculature in inflammatory bowel disease. European Journal of Immunology, 2009, 39, 290-300.	1.6	52
31	COVID-19 Digestive System Involvement and Clinical Outcomes in a Large Academic Hospital in Milan, Italy. Clinical Gastroenterology and Hepatology, 2020, 18, 2366-2368.e3.	2.4	51
32	Presence of Twist1-Positive Neoplastic Cells in the Stroma ofÂChromosome-Unstable Colorectal Tumors. Gastroenterology, 2013, 145, 647-657.e15.	0.6	49
33	Open label trial of granulocyte apheresis suggests therapeutic efficacy in chronically active steroid refractory ulcerative colitis. World Journal of Gastroenterology, 2005, 11, 7001.	1.4	49
34	MFSD2A Promotes Endothelial Generation of Inflammation-Resolving Lipid Mediators and Reduces ColitisÂinÂMice. Gastroenterology, 2017, 153, 1363-1377.e6.	0.6	48
35	Narrow-band imaging endoscopy to assess mucosal angiogenesis in inflammatory bowel disease: A pilot study. World Journal of Gastroenterology, 2010, 16, 2396.	1.4	48
36	Endoluminal Fundoplication (ELF) for GERD Using EsophyX: a 12-Month Follow-up in a Single-Center Experience. Journal of Gastrointestinal Surgery, 2010, 14, 1-6.	0.9	47

#	Article	IF	CITATIONS
37	Endoscopic Ultrasonography and Magnetic Resonance in Preoperative Staging of Rectal Cancer: Comparison With Histologic Findings. Journal of Gastrointestinal Surgery, 2005, 9, 1222-1228.	0.9	42
38	Anti-adhesion molecule therapies in inflammatory bowel disease: Touch and go. Autoimmunity Reviews, 2008, 7, 364-369.	2.5	42
39	Calcium supplementation for the prevention of colorectal adenomas: A systematic review and meta-analysis of randomized controlled trials. World Journal of Gastroenterology, 2016, 22, 4594.	1.4	42
40	Insulated-Tip Knife Endoscopic Mucosal Resection of Large Colorectal Polyps Unsuitable for Standard Polypectomy. American Journal of Gastroenterology, 2007, 102, 1617-1623.	0.2	40
41	Microsatellite Instability and Therapeutic Consequences in Colorectal Cancer. Digestive Diseases, 2012, 30, 304-309.	0.8	39
42	The urokinase plasminogen activator receptor (uPAR) controls macrophage phagocytosis in intestinal inflammation. Gut, 2015, 64, 589-600.	6.1	39
43	Clinical Utility of the Serum CA 19-9 Test for Diagnosing Pancreatic Carcinoma in Symptomatic Patients. Pancreas, 1992, 7, 497-502.	0.5	37
44	Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease. Expert Review of Clinical Immunology, 2010, 6, 567-572.	1.3	37
45	Genetic and epigenetic alterations in primary colorectal cancers and related lymph node and liver metastases. Cancer, 2013, 119, 266-276.	2.0	34
46	Evolving notions on immune response in colorectal cancer and their implications for biomarker development. Inflammation Research, 2018, 67, 375-389.	1.6	32
47	Re: Revised Bethesda Guidelines for Hereditary Nonpolyposis Colorectal Cancer (Lynch Syndrome) and Microsatellite Instability. Journal of the National Cancer Institute, 2004, 96, 1402-1403.	3.0	30
48	Endoscopic submucosal dissection of early gastric neoplastic lesions. European Journal of Gastroenterology and Hepatology, 2013, 25, 1261-1264.	0.8	30
49	KRAS mutation in lung metastases from colorectal cancer: prognostic implications. Cancer Medicine, 2016, 5, 256-264.	1.3	29
50	Combined Low Densities of FoxP3+ and CD3+ Tumor-Infiltrating Lymphocytes Identify Stage II Colorectal Cancer at High Risk of Progression. Cancer Immunology Research, 2019, 7, 751-758.	1.6	29
51	Biological agents for ulcerative colitis: Hypes and hopes. Medicinal Research Reviews, 2008, 28, 201-218.	5.0	24
52	Emerging Biologics in the Treatment of Inflammatory Bowel Disease: What is Around the Corner?. Current Drug Targets, 2010, 11, 249-260.	1.0	24
53	Frameshift Mutations of Human Gastrin Receptor Gene (hGARE) in Gastrointestinal Cancers with Microsatellite Instability. Laboratory Investigation, 2002, 82, 265-271.	1.7	21
54	Successful induction of clinical response and remission with certolizumab pegol in Crohn's disease patients refractory or intolerant to infliximab: A real-life multicenter experience of compassionate use. Inflammatory Bowel Diseases, 2008, 14, 1168-1170.	0.9	21

#	Article	IF	CITATIONS
55	MSH3 Protein Expression and Nodal Status in MLH1-Deficient Colorectal Cancers. Clinical Cancer Research, 2012, 18, 3142-3153.	3.2	21
56	Prognostic and Predictive Cross-Roads of Microsatellite Instability and Immune Response to Colon Cancer. International Journal of Molecular Sciences, 2020, 21, 9680.	1.8	17
57	Lymphatic endothelium contributes to colorectal cancer growth via the soluble matrisome component GDF11. International Journal of Cancer, 2019, 145, 1913-1920.	2.3	16
58	Enhanced platelet adhesion induces angiogenesis in intestinal inflammation and inflammatory bowel disease microvasculature. Journal of Cellular and Molecular Medicine, 2011, 15, 625-634.	1.6	15
59	Hereditary or sporadic polyposis syndromes. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2017, 31, 409-417.	1.0	15
60	Treatment with a Urokinase Receptor-derived Cyclized Peptide Improves Experimental Colitis by Preventing Monocyte Recruitment and Macrophage Polarization. Inflammatory Bowel Diseases, 2016, 22, 2390-2401.	0.9	14
61	Pancreatic cancer or chronic pancreatitis? An answer from PET/MRI image fusion. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, 1352.	3.3	13
62	Cytapheresis in Inflammatory Bowel Diseases: Current Evidence and Perspectives. Digestion, 2008, 77, 96-107.	1.2	13
63	Nissen Fundoplication after Failure of Endoluminal Fundoplication: Short-Term Results. Journal of Gastrointestinal Surgery, 2011, 15, 439-443.	0.9	13
64	mTOR-Dependent Stimulation of IL20RA Orchestrates Immune Cell Trafficking through Lymphatic Endothelium in Patients with Crohn's Disease. Cells, 2019, 8, 924.	1.8	12
65	Tumor Necrosis Factor-Alpha Monoclonal Antibodies for Crohns Disease: Tipping the Balance. Current Medicinal Chemistry, 2007, 14, 1489-1497.	1.2	11
66	Gender difference for promoter methylation pattern of hMLH1 and p16 in sporadic MSI colorectal cancer. Gastroenterology, 2003, 124, 1165-1166.	0.6	10
67	Successful treatment of fistulizing Crohn's disease with certolizumab pegol. Inflammatory Bowel Diseases, 2008, 14, 292-293.	0.9	9
68	Heterogeneity of Colorectal Cancer Progression: Molecular Gas and Brakes. International Journal of Molecular Sciences, 2021, 22, 5246.	1.8	9
69	Epithelial to Mesenchymal Transition: A Challenging Playground for Translational Research. Current Models and Focus on TWIST1 Relevance and Gastrointestinal Cancers. International Journal of Molecular Sciences, 2021, 22, 11469.	1.8	9
70	Novel Prognostic Biomarkers in Colorectal Cancer. Digestive Diseases, 2012, 30, 296-303.	0.8	7
71	Constraints imposed by supercoiling on in vitro amplification of polyomavirus DNA. Journal of General Virology, 2004, 85, 3383-3388.	1.3	7
72	Prognostic Value of Colorectal Cancer Biomarkers. Cancers, 2011, 3, 2080-2105.	1.7	5

5

#	Article	IF	CITATIONS
73	A case of esophageal squamous cell intraepithelial neoplasia with positivity for type 16 human papillomavirus successfully treated with radiofrequency ablation. Journal of Gastrointestinal Oncology, 2014, 5, E36-9.	0.6	5
74	Tumorâ€associated macrophages and risk of recurrence in stage <scp>III</scp> colorectal cancer. Journal of Pathology: Clinical Research, 2022, 8, 307-312.	1.3	5
75	Pancreatic polypeptide secretion after insulin infusion and protein meal in juvenile type 1 diabetic subjects. Acta Diabetologica Latina, 1990, 27, 165-171.	0.2	4
76	Pancreatic Polypeptide Response to Food and Cerulein in Patients with Total Gastrectomy. Pancreas, 1989, 4, 538-542.	0.5	3
77	Closure of perianal fistula using adalimumab in a Crohn's disease patient naive to antitumor necrosis factor alpha antibodies. Inflammatory Bowel Diseases, 2009, 15, 814-815.	0.9	3
78	How dense, how intense? Role of tumourâ€infiltrating lymphocytes across colorectal cancer stages. Re: Nosho <i>et al</i> . Tumourâ€infiltrating Tâ€cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. <i>J Pathol</i> 2010; 222: 350–366. Journal of Pathology, 2011, 225, 628-628.	2.1	3
79	T1687 Infliximab Inhibits Mucosal Pathological Angiogenesis in Crohn's Disease. Gastroenterology, 2009, 136, A-558.	0.6	1
80	Reply to the Letter to the Editor from Watanabe et al. Clinical Cancer Research, 2008, 14, 2516-2516.	3.2	0